CLK-IN-T3

• CAT Number: I017436
• CAS Number: 2109805-56-1
• Molecular Formula: C₂₈H₃₀N₆O₂
• Molecular Weight: 482.58
• Purity: ≥95%
• IUPAC Name: 4-[2-methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl]-N-(6-pyridin-4-ylimidazo[1,2-a]pyridin-2-yl)benzamide
• InChI: InChI=1S/C28H30N6O2/c1-28(2,27(36)33-16-14-32(3)15-17-33)23-7-4-21(5-8-23)26(35)31-24-19-34-18-22(6-9-25(34)30-24)20-10-12-29-13-11-20/h4-13,18-19H,14-17H2,1-3H3,(H,31,35)
• InChIKey: IEFFSHLHNYVSEF-UHFFFAOYSA-N
• SMILES: CC(C)(C1=CC=C(C=C1)C(=O)NC2=CN3C=C(C=CC3=N2)C4=CC=NC=C4)C(=O)N5CCN(CC5)C

CLK-IN-T3（Cat No.:I017436）is a potent and selective inhibitor of CDC-like kinases (CLKs), a family of serine/threonine kinases involved in regulating RNA splicing through the phosphorylation of splicing factors. By inhibiting CLKs, CLK-IN-T3 disrupts the alternative splicing of pre-mRNA, which can affect gene expression patterns. This makes it a valuable tool for studying RNA splicing mechanisms and exploring therapeutic applications, particularly in diseases like cancer and neurodegenerative disorders, where aberrant splicing plays a role. CLK-IN-T3 has shown promise in preclinical studies, providing insights into novel treatment strategies for splicing-related diseases.

Reference

[1]. Funnell T, et al. CLK-dependent exon recognition and conjoined gene formation revealed with a novel smallmolecule inhibitor. Nat Commun. 2017 Feb 23;8(1):7.